Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0

作者：

Mezquita, L. ^{[1
]}

Remon, J. ^{[1
]}

Nicotra, C. ^{[2
]}

Noerholm, M. ^{[3
]}

Brinkmann, K. ^{[3
]}

Planchard, D. ^{[4
]}

Jovelet, C. ^{[5
]}

Auclin, E. ^{[6
]}

Flinspach, C. ^{[3
]}

Hurley, J. ^{[3
]}

Skog, J. ^{[7
]}

Gazzah, A. ^{[2
]}

Caramella, C. ^{[8
]}

Adam, J. ^{[9
]}

Lacroix, L. ^{[5
]}

Auger, N. ^{[9
]}

Friboulet, L. ^{[10
]}

Soria, J. ^{[11
,12
]}

Besse, B. ^{[1
]}

机构：

[1] Gustave Roussy, Dept Med Oncol, Villejuif, France

[2] Gustave Roussy, Drug Dev Dept, Villejuif, France

[3] Exosome Diagnost GmbH, Martinsried, Germany

[4] Gustave Roussy, Med Oncol, Villejuif, France

[5] Gustave Roussy, Translat Res Lab, Villejuif, France

[6] Hop Georges Pompidou, Paris, France

[7] Exosome Diagnost Inc, Waltham, MA USA

[8] Gustave Roussy, Radiol Dept, Villejuif, France

[9] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France

[10] Gustave Roussy, Inserm U981 Lab, Villejuif, France

[11] Gustave Roussy Canc Campus, Drug Dev Dept, Paris, France

[12] Gustave Roussy Canc Campus, Inserm U981 Lab, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.03-013

引用

页码：S1954 / S1955

页数：2

共 50 条

[41] EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).
Dinh, M.
Pithavala, Y.
Chen, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S19 - S19
[42] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
Salgia, Ravi
Solomon, Benjamin J.
Shaw, Alice Tsang
Camidge, D. Ross
Evans, Tracey L.
Kim, Dong-Wan
Shi, Yuankai
Han, Ji-Youn
De Pas, Tommaso Martino
Ou, Sai-Hong Ignatius
Bartlett, Cynthia Huang
Wilner, Keith D.
Reisman, Arlene
Iyer, Shrividya
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[43] VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB
Besse, B.
Salgia, R.
Solomon, B.
Shaw, A.
Kim, D.
Schachar, R.
Wilner, K.
Reisman, A.
Bartlett, C. H.
Iyer, S.
ANNALS OF ONCOLOGY, 2012, 23 : 416 - 416
[44] Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
Shirish M. Gadgeel
Current Treatment Options in Oncology, 2017, 18
[45] TUMOR BURDEN AND TYROSINE KINASE INHIBITORS (TKI) BENEFIT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR SENSITIZING MUTATIONS (EGFRM) AND ALK REARRANGEMENT (ALK plus )
Leduc, C.
Moussa, N.
Faivre, L.
Biondani, P.
Pignon, J.
Caramella, C.
Besse, B.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S37 - S37
[46] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
Gadgeel, Shirish M.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
[47] ALK rearrangement in non-small cell lung cancer
Naulleau, Gaspard
Birsen, Gary
Mansuet-Lupo, Audrey
Leroy, Karen
Wislez, Marie
BULLETIN DU CANCER, 2025, 112 (03) : 3S86 - 3S94
[48] EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
de Mello, Ramon Andrade
Madureira, Pedro
Carvalho, Liliana S.
Araujo, Antonio
O'Brien, Mary
Popat, Sanjay
PHARMACOGENOMICS, 2013, 14 (14) : 1765 - 1777
[49] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
De Carlo, Elisa
Stanzione, Brigida
Del Conte, Alessandro
Revelant, Alberto
Bearz, Alessandra
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
[50] Future options for ALK-positive non-small cell lung cancer
Iacono, Daniela
Chiari, Rita
Metro, Giulio
Bennati, Chiara
Bellezza, Guido
Cenci, Matteo
Ricciuti, Biagio
Sidoni, Angelo
Baglivo, Sara
Minotti, Vincenzo
Crino, Lucio
LUNG CANCER, 2015, 87 (03) : 211 - 219

← 1 2 3 4 5 →